Cyclerion Therapeutics, Inc. (NASDAQ:KRSA - Get Free Report) crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $32.09 and traded as high as $34.18. Cyclerion Therapeutics shares last traded at $32.68, with a volume of 319,840 shares trading hands.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. UBS Group assumed coverage on Cyclerion Therapeutics in a research note on Friday, September 11th. They issued a "buy" rating and a $55.00 price target on the stock. Guggenheim started coverage on shares of Cyclerion Therapeutics in a report on Monday, September 28th. They issued a "buy" rating and a $70.00 price objective for the company. Wedbush initiated coverage on shares of Cyclerion Therapeutics in a research note on Monday, October 5th. They set an "outperform" rating and a $44.00 target price on the stock. Wells Fargo & Company assumed coverage on Cyclerion Therapeutics in a research note on Friday. They issued an "overweight" rating and a $44.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a "buy" rating and a $43.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.20.
Read Our Latest Report on KRSA
Cyclerion Therapeutics Price Performance
The stock has a market cap of $1.49 billion, a PE ratio of -2.57 and a beta of 1.85. The firm's 50-day simple moving average is $32.09.
Cyclerion Therapeutics (NASDAQ:KRSA - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($3.19) earnings per share for the quarter, topping the consensus estimate of ($50.40) by $47.21. As a group, equities research analysts anticipate that Cyclerion Therapeutics, Inc. will post -5.35 EPS for the current year.
Hedge Funds Weigh In On Cyclerion Therapeutics
Several large investors have recently made changes to their positions in KRSA. ADAR1 Capital Management LLC purchased a new stake in shares of Cyclerion Therapeutics during the second quarter worth about $1,013,000. Braidwell LP bought a new stake in Cyclerion Therapeutics during the 2nd quarter valued at approximately $532,000. Finally, BlackRock Inc. purchased a new position in Cyclerion Therapeutics in the 2nd quarter worth approximately $57,000. 75.62% of the stock is currently owned by hedge funds and other institutional investors.
Cyclerion Therapeutics Company Profile
(
Get Free Report)
Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion's development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer's disease and other neurological disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cyclerion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclerion Therapeutics wasn't on the list.
While Cyclerion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.